For the nine months ended September 30, 2026, QHSLab, Inc. reported revenue of $2,253,347, an increase from $1,987,931 in the prior year period, though it incurred a net loss of $119,021. The company faces a going concern uncertainty due to an accumulated deficit of over $4 million and negative cash flows from operations.
Bluejay Diagnostics reported a net loss of $6.26 million for the nine months ended September 30, 2026, compared to $5.42 million in the prior year period. The company strengthened its cash position to $7.38 million through private placements and warrant exercises, while continuing to invest heavily in research and development for its diagnostic platform.
Motorsport Games Inc. filed its Form 10-Q for the quarter ended September 30, 2026, reporting 4,588,802 shares of Class A common stock outstanding. The company highlighted significant liquidity concerns, noting that its product roadmap and operations remain subject to adjustments based on its ability to secure additional debt or equity financing.
Aeluma, Inc. reported a significant revenue decline to $0.57 million for the quarter ended September 30, 2026, compared to $1.39 million in the prior year, while net loss widened to $3.76 million due to a fourfold increase in research and development expenses. Despite the increased burn rate, the company maintains a strong liquidity position with $53.88 million in cash and cash equivalents.
Diodes Incorporated reported its third quarter 2026 financial results and hosted an earnings conference call to discuss business performance and outlook. The company provided preliminary results for the period ended September 30, 2026, and furnished a full transcript of the management discussion and Q&A session.
Bio Green Med Solution reported Q3 2026 financial results, highlighting a significant increase in fire safety product revenue to $454,000 and a narrowed net loss of $0.4 million. The company also announced that its Form S-4 for the proposed business combination with Future NRG Sdn. Bhd. has been declared effective, with a shareholder vote planned for November 2026.
Term
Q3 2026
“During the third quarter, our fire safety business generated $454,000 in product revenue, compared to $81,000 in the prior-year period, and yielded a gross margin of approximately 25%, while our net loss narrowed to $0.4 million from $1.0 million in the prior-year period.”
Datuk Dr. Doris Wong Sing Ee, Chief Executive Officer and Executive Director
“We also reduced general and administrative expenses by 37% year over year and ended the quarter with $3.5 million in cash and cash equivalents.”
Datuk Dr. Doris Wong Sing Ee, Chief Executive Officer and Executive Director
Xenetic Biosciences reported a net loss of $3.1 million for the nine months ended September 30, 2026, compared to $2.1 million in the prior year period, driven primarily by a significant increase in general and administrative expenses. Total revenue, derived from royalties, remained relatively flat at $2.2 million for the nine-month period. The company ended the quarter with $5.8 million in cash and is focused on advancing its systemic DNase program into clinical trials.
LifeMD, Inc. reported a net loss of $20.6 million for the nine months ended September 30, 2026, compared to a $5.2 million loss in the prior year period. While telehealth revenue remained significant at $142 million, the company experienced an operating loss from continuing operations of $20.7 million as selling and marketing expenses increased to $76.4 million.
Peraso Inc. reported third quarter 2026 financial results, with total net revenue of $0.3 million, significantly down from $3.2 million in the prior year due to irregular order patterns in the fixed wireless access market. The company highlighted a recent $2 million production order in October and a $10 million private placement with Nant Capital that strengthened its financial position, leading the board to conclude its review of strategic alternatives.
Term
3 months
“Our third-quarter results reflected the previously indicated headwinds from irregular order patterns among our customers in the fixed wireless access market. That said, we have begun to see early signs of renewed customer demand in the fourth quarter.”
Ron Glibbery, CEO of Peraso
“Looking forward, we believe the breadth of our customer engagements, and the growing recognition of 60 GHz technology, positions Peraso to return to revenue growth beginning in the fourth quarter.”
Gores Holdings XI, Inc. reported a net income of $1,912,334 for the nine months ended September 30, 2026, primarily driven by $3,479,479 in interest income from its Trust Account. The company completed its Initial Public Offering in June 2026, raising $358.8 million, and is currently a shell company seeking a business combination.
Solésence, Inc. reported a net income of $3.67 million for the third quarter of 2026, a significant recovery from a $1.02 million net loss in the prior year period, driven by a 38% increase in total revenue. For the nine months ended September 30, 2026, the company generated $8.4 million in cash from operating activities, compared to a $10.4 million cash burn in the same period of 2025.
SVRE Holdings Ltd. reported a net loss of $11.1 million for the first quarter of 2026, compared to a net income of $13.6 million in the prior year period, primarily due to higher financial expenses and lower foreign currency exchange gains. The company significantly strengthened its liquidity position, ending the quarter with $110.4 million in cash after securing a $297 million DFC loan facility to fund the development of its Pela Ema rare earth project.
Private Bancorp of America, Inc. reported net income of $36.6 million for the nine months ended September 30, 2026, an increase from $30.7 million in the prior year period. Total assets grew to $2.75 billion, driven by increases in cash equivalents and debt securities, while net interest income improved significantly due to higher interest and fees on loans.
Spruce Power reported third quarter 2026 financial results, achieving net income of $6.0 million compared to a net loss in the prior year period. The company highlighted a 23% year-over-year reduction in SG&A expenses driven by streamlining efforts and the use of AI in operations, contributing to a 52% increase in Adjusted Cash Flow from Operations.
Term
Q3 2026
“Our third quarter 2026 results reflect continued cost discipline and steady operational execution. Most importantly, subsequent to quarter end we met the October 30 milestone by executing a non-binding term sheet for the refinancing of SP1, SP2, and SP3. Meeting this important milestone extended the maturity of the SP1 facility to January 30, 2027.”
Chris Hayes, Chief Executive Officer
“During the quarter we continued to see the positive effects of the streamlining efforts we implemented last fall. SG&A expenses were reduced by 23% compared to last year, reflecting both the structural efficiencies we have built into the operating model and the aggressive new programs to implement labor savings across our operational functions through the targeted use of AI.”
1st Franklin Financial Corp reported net income of $19.1 million for the nine months ended September 30, 2026, a significant increase from $12.1 million in the prior year period. Total assets grew slightly to $1.47 billion, while the company experienced a notable increase in interest income and a higher provision for credit losses.
KinderCare Learning Companies reported a significant net loss of $383.6 million for the nine months ended October 3, 2026, primarily driven by $401.2 million in impairment losses. Revenue remained relatively flat year-over-year at approximately $2.04 billion, while total shareholders' equity decreased from $755.3 million to $385.0 million during the period.
TMC the metals company Inc. reported a significant increase in exploration and evaluation expenses to $92.9 million for the nine months ended September 30, 2026, compared to $29.6 million in the prior year. The company recorded a net operating loss of $138.7 million for the same period, while its cash position decreased to $79.3 million from $117.6 million at year-end 2025.
First Eagle Private Credit Fund reported total non-controlled/non-affiliated investments at a fair value of $526.5 million as of September 30, 2026, a decrease from $567.3 million at year-end 2025. The fund maintained $38.5 million in cash and cash equivalents and reported 12,844,156 Class I shares outstanding as of November 12, 2026.
Marblegate Capital Corp reported a net loss of $9.8 million for the nine months ended September 30, 2026, compared to a $52.3 million loss in the prior year period. While total revenue grew to $47.2 million driven by fleet operations, the company faced increased operating expenses and net losses on loans held for investment.
For the nine months ended September 30, 2026, Andalusian Credit Company, LLC reported total investment income of $30.5 million and net investment income of $13.2 million. Total net assets grew to $417.5 million, driven by $71.1 million in share issuance proceeds, while the net asset value per share increased slightly to $15.33.
InspireMD reported third quarter 2026 financial results, highlighted by total revenue of $2.2 million, a 9% increase year-over-year driven by international performance. During the quarter, the company received FDA approval for its CGuard Prime carotid stent system for TCAR procedures, which is expected to double its U.S. addressable market with a commercial launch planned for Q4 2026.
Term
Q3 2026
“FDA approval of CGuard Prime for TCAR procedures represents a transformative milestone for InspireMD, enabling the launch of our next-g”
Bio Green Med Solution, Inc. is undergoing a significant business combination with Future NRG Sdn. Bhd. (FNRG), which will result in FNRG shareholders owning over 99% of the combined company. The company recently deconsolidated its former subsidiary, Cyclacel Limited, following a creditors voluntary liquidation and has pivoted its business focus through various asset sales and exchange agreements.
Aeluma reported Q1 fiscal 2027 financial results with revenue of $0.6M and a net loss of $3.8M. The company highlighted a new purchase agreement with Aixtron for MOCVD manufacturing expansion and ongoing negotiations for $30M in CHIPS Act funding.
Term
Q1 2027
“The current U.S. AI infrastructure buildout continues to progress and is expected to reach an aggregate investment of $10.3 trillion in 2032. The opportunities for photonics are vast, spanning scale-up and scale-out AI architectures in data centers.”
Jonathan Klamkin, Ph.D., Founder and CEO
“As we progress through fiscal 2027, we remain focused on technology and product development for AI Datacom opportunities. Aeluma’s high-speed photodetectors and quantum dot lasers continue to attract customer attention.”
Sutro Biopharma reported third quarter 2026 financial results, highlighting a cash position of $142.2 million which is expected to fund operations into the first half of 2028. The company advanced its clinical pipeline with the first patient dosed in the STRO-006 Phase 1 study and reported progress on its STRO-004 and STRO-227 ADC programs.
Term
3 months
“Over the past year, we have delivered on our commitment to advance our next-generation ADCs with two programs, STRO-004 and STRO-006, entering the clinic in less than a year, and our dual-payload ADC, STRO-227, expected to follow in early 2027.”
Jane Chung, Chief Executive Officer of Sutro
“Early data from STRO-004 give us confidence in its potential to deliver meaningful clinical benefit with our proprietary ADC platform. In addition, our collaboration partner Astellas has initiated patient dosing with a second dual-payload immunostimulatory ADC, further highlighting our strong execution and ability to deliver differentiated, novel dual-payload ADCs.”
PIMCO Capital Solutions BDC Corp. reported that non-qualifying assets represented 1.7% of total net assets as of September 30, 2026, down from 3.2% at year-end 2025. The company also disclosed a significant affiliated investment in Voyatek with a fair value of approximately $23.1 million and noted that its credit facility's unused commitment fee expired in June 2026.
Spero Therapeutics reported third quarter 2026 financial results, ending the period with $107.9 million in cash and cash equivalents. The company is focused on advancing its in-licensed anti-CD40L antibody, SP001, toward a Phase 2 trial in IgG4-related disease expected to initiate in Q2 2027.
“We believe SP001 represents a compelling opportunity to address significant unmet medical needs across multiple immune-mediated diseases. With a strong financial position and the recent additions to our team that strengthen the capabilities needed to support our next stage of development, we believe we are well positioned to execute our clinical development strategy.”
Esther Rajavelu, President and Chief Executive Officer
Battalion Oil Corp reported total operating revenues of $45.6 million for the quarter ended September 30, 2026, with a net income from operations of $5.0 million. However, the company faced a significant net loss on derivative contracts of $44.8 million during the quarter, compared to a gain in the prior year period.
Silexion Therapeutics Corp is a development-stage biotechnology company focused on its Phase 2/3 clinical trial of SIL204 for pancreatic cancer. As of November 12, 2026, the company reported 649,528 ordinary shares outstanding and continues to operate as an emerging growth company with no product revenue to date.
Innovative Food Holdings reported a consolidated net income of $2.03 million for the nine months ended September 30, 2026, a significant recovery from a $2.09 million loss in the prior year period. This improvement was driven by a $1.5 million gain from discontinued operations and a $2.69 million gain on the disposition of assets, despite a decrease in total revenue from $47.3 million to $37.2 million.
DiaMedica Therapeutics reported a net loss of $31.5 million for the nine months ended September 30, 2026, driven by increased research and development expenses for its lead candidate DM199. The company's cash and marketable securities decreased to $34.9 million from $59.9 million at the end of 2025, reflecting ongoing clinical trial costs for preeclampsia and fetal growth restriction programs.